PYC pyc therapeutics limited

0.40%

$1.27

My guess after another couple of years they’ll be backed into...

First 25 Last

Share
Profile

Follow
Akki

35,790 Posts.

555

01/08/19

12:05

Post #: 39808858
Share

Originally posted by andrewk65 ↑

I certainly agree with you Hesk when you ask what is going on. For the history of the company it seems we are told we are on the edge, on the verge, at the forefront etc, yet here we are. I have never found a way yet to confirm truly if anyone is interested in anything we are doing. Even communicating with the company the same info comes back, seeming to indicate there is much interest but we are not quite there. Ultimately the only ones who know are directors and they bought more than most of us.

At the moment it seems to be one giant quandary as on the one hand a couple of board members own a huge number of shares so the bosses have no reason to sit back and burn cash. On the other hand we are told what we are doing is ground breaking yet obviously no deals and realistically nothing said that indicates we have interested parties in our offices looking for a reason to sign.
i guess one component could be that they did clearly state they were no longer targetting small collaboration type deals like previous ones. In the past i think the only reason we got the deals we did was because they were ridiculously cheap for what they were. Maybe we could have 2 or 3 right now if that was what we wanted but maybe that is why Rohan is busy, trying to lock in a significant deal rather than another free access to our tech type collaboration where we tie up our now quite expensive labs and scans for months or years on someone elses target for 500k or 1 mil. Even genentech shows this o guess, with initial payment and then extension not amounting to much more than 3 million for around 5 years of collaboration?

Expand

My guess after another couple of years they’ll be backed into another “new” biotech with equally rosey ideals for about $100m in scrip ..... and it will start again

PYC Price at posting: 3.3¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

'Not possible' to port renewable gas: ACCC takes AGN to court

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

First 25 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.27		Change 0.005(0.40%)		Mkt cap ! $740.7M

Open	High	Low	Value	Volume
$1.27	$1.29	$1.27	$406.0K	319.3K

Buyers (Bids)

No.	Vol.	Price($)
1	13987	$1.27

Sellers (Offers)

Price($)	Vol.	No.
$1.29	1380	1

View Market Depth

No.	Vol.	Price($)
1	13987	1.265
2	16380	1.260
3	14380	1.255
3	103380	1.250
1	4000	1.225

Price($)	Vol.	No.
1.285	1380	1
1.290	27010	3
1.295	25880	2
1.300	59168	4
1.325	9001	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

PYC (ASX) Chart

My guess after another couple of years they’ll be backed into...

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

'Not possible' to port renewable gas: ACCC takes AGN to court

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

My guess after another couple of years they’ll be backed into...

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

'Not possible' to port renewable gas: ACCC takes AGN to court

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News